# Effects of Levosimendan on Cardiac Function After TAVR in Patients With Heart Failure

Study · id `cardio:ct-nct06196177` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06196177](<https://clinicaltrials.gov/study/NCT06196177>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06196177

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 112 participants.

## Technical summary

Registry record NCT06196177. Randomized; single masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 112 participants (planned count; ClinicalTrials.gov record NCT06196177, source copy `cardio:ctgov-nct06196177-2024-04-03`, retrieved 2026-10-26)
- Started: 2024-03-01 (actual) (ClinicalTrials.gov record NCT06196177, source copy `cardio:ctgov-nct06196177-2024-04-03`, retrieved 2026-10-26)
- Primary completion: 2025-01 (anticipated) (ClinicalTrials.gov record NCT06196177, source copy `cardio:ctgov-nct06196177-2024-04-03`, retrieved 2026-10-26)
- Completion: 2025-02 (anticipated) (ClinicalTrials.gov record NCT06196177, source copy `cardio:ctgov-nct06196177-2024-04-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06196177, source copy `cardio:ctgov-nct06196177-2024-04-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06196177-2024-04-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Levosimendan on Cardiac Function After TAVR in Patients With Heart Failure
- Condition: Heart Failure
- Condition: Aortic Stenosis, Severe
- Intervention (Drug): Levosimontane injection
- Lead sponsor: Qilu Hospital of Shandong University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Qilu Hospital of Shandong University (`cardio:org-qilu-hospital-of-shandong-university`)

## Provenance

Content hash: 5eec686319bee4feafe3a748874e53c6b22024633bcf61653bb6ffa23c52116f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
